Astrazeneca (AZN) reported $13.59 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 7.2%. EPS of $1.24 for the same period compares to $1.03 a year ago.

The reported revenue represents a surprise of -0.66% over the Zacks Consensus Estimate of $13.68 billion. With the consensus EPS estimate being $1.10, the EPS surprise was +12.73%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Oncology- Tagrisso- U.S. $678 million compared to the $684.78 million average estimate based on three analysts.
• BioPharmaceuticals- CVRM- Farxiga- Established RoW: $120 million versus the three-analyst average estimate of $101.67 million. The reported number represents a year-over-year change of +11.1%.
• Oncology- Enhertu- Established RoW: $19 million versus the three-analyst average estimate of $21.59 million. The reported number represents a year-over-year change of +46.2%.
• Oncology- Enhertu- Europe: $43 million versus the three-analyst average estimate of $36.98 million. The reported number represents a year-over-year change of +65.4%.
• BioPharmaceuticals- R&I- Symbicort- World: $723 million versus the three-analyst average estimate of $772.02 million.
• BioPharmaceuticals- R&I- Pulmicort- World: $158 million compared to the $197.96 million average estimate based on three analysts.
• BioPharmaceuticals- CVRM- Crestor- World: $316 million compared to the $294.03 million average estimate based on three analysts. The reported number represents a change of +6.4% year over year.
• BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $161 million versus the three-analyst average estimate of $154.45 million. The reported number represents a year-over-year change of -2.4%.
• Oncology- Tagrisso- World: $1.68 billion compared to the $1.67 billion average estimate based on three analysts. The reported number represents a change of +5.3% year over year.
• BioPharmaceuticals- V&I- Synagis- World: $112 million versus the three-analyst average estimate of $132.88 million. The reported number represents a year-over-year change of -34.5%.
• BioPharmaceuticals- R&I- Fasenra- World: $418 million compared to the $379.51 million average estimate based on three analysts.
• BioPharmaceuticals- CVRM- Brilinta- World: $305 million versus the three-analyst average estimate of $263.03 million. The reported number represents a year-over-year change of -5.6%.

View all Key Company Metrics for Astrazeneca here>>>

Shares of Astrazeneca have returned -4.9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research